Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Diffuse Large B-cell Lymphoma
Clinical trial register · Czechia

Diffuse Large B-cell Lymphoma Trials in Czechia, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Czechia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1513 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:18 UTC
1513
Studies in scope
all four open statuses
780
Recruiting now
open to new participants
300
Lead sponsors
across recruiting studies
Top sites
Prague 10 Hradec Králové 7 Brno 5 Ostrava 5 Olomouc 3
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Diffuse Large B-cell Lymphoma trials in Czechia

12 of 1513 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Czechia
Start
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
Merck Sharp & Dohme LLC
Phase 1/2
90
Brno, Prague
2024-08-16
Active, closed
Incyte Corporation
Phase 3
82
Olomouc, Prague
2022-12-23
Active, closed
Incyte Corporation
Phase 1/2
53
Brno, Ostrava, Prague
2022-07-19
Recruiting
Miltenyi Biomedicine GmbH
Phase 2
213
Hradec Králové, Ostrava
2021-08-18
Active, closed
Incyte Corporation
Phase 3
899
Brno, Hradec Králové, Olomouc, Ostrava, Prague
2021-05-11
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Kartos Therapeutics, Inc.
Phase 1/2
84
Nový Hradec Králové, Ostrava, Prague
2021-02-23
Active, closed
Genmab
Phase 1/2
543
Hradec Králové, Ostrava - Poruba, Prague
2020-11-03
Active, closed
Acerta Pharma BV
Phase 3
611
Brno, Hradec Králové, Ostrava - Poruba, Pilsen, Prague
2020-10-08
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
240
Hradec Králové
2020-08-20
Active, closed
Duke University
Not applicable
243
Prague
2019-02-13
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Czech investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-czechia/condition/diffuse-large-b-cell-lymphoma

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Czechia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,513 studies in total at the last sync on 11 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies listing the condition Diffuse Large B-cell Lymphoma.

How many Diffuse Large B-cell Lymphoma trials are recruiting in Czechia?

3 of the 12 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Diffuse Large B-cell Lymphoma), 12 studies
PhaseStudiesRecruitingShare
Phase 36050%
Phase 1/24233.3%
Not applicable108.3%
Phase 2118.3%

Most active sponsors

Lead sponsors with the most studies (Diffuse Large B-cell Lymphoma)
Lead sponsorStudiesRecruiting
Genmab30
Incyte Corporation30
Acerta Pharma BV10
Duke University10
Kartos Therapeutics, Inc.11
Merck Sharp & Dohme LLC11
Miltenyi Biomedicine GmbH11
Seagen, a wholly owned subsidiary of Pfizer10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.